Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NDI-5001
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Recipient : NephroDI Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement aims for the clinical development of NephroDI’s asset, NDI-5001, a novel kidney-targeted small molecule AMPK activator, as a potential therapy for X-linked congenital Nephrogenic Diabetes Insipidus (NDI).
Brand Name : NDI-5001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 22, 2023
Lead Product(s) : NDI-5001
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Recipient : NephroDI Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : IRL757
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Recipient : IRLAB
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement aims to evaluate IRLAB’s neuropsychiatric programs IRL757 and IRL942. Drug candidate IRL757 is being developed as a treatment for apathy in neurological disorders such as Parkinson’s, Alzheimer’s disease with a once-daily oral adminis...
Brand Name : IRL757
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 16, 2023
Lead Product(s) : IRL757
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Recipient : IRLAB
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : SOL784
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Sentinel Oncology
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, MSRD and Sentinel will collaborate to support the Phase 1a and Phase 1b clinical trials for Sentinel’s investigational compound SOL784 with the opportunity to expand the collaboration after those studies.
Brand Name : SOL784
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 03, 2021
Lead Product(s) : SOL784
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Sentinel Oncology
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : ACH000029
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Recipient : Ache Laboratorios Farmaceuticos SA
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, MSRD and Aché will collaborate to advance Aché’s novel compound ACH000029 through phase 1b clinical trials with the opportunity to expand the collaboration after those studies.
Brand Name : ACH000029
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 24, 2021
Lead Product(s) : ACH000029
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Recipient : Ache Laboratorios Farmaceuticos SA
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Eikonizo Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, MSRD and Eikonizo will collaborate to advance Eikonizo’s HDAC6 inhibitors through preclinical and Phase 1b clinical studies respectively, with the opportunity to expand the collaboration after those studies.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 09, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Eikonizo Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Rugen Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Activities will support the clinical development of Rugen’s potential first-in-class, orally administered drug candidate with initial clinical focus on treatment-resistant depression.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 30, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Rugen Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?